Abstract: OBJECTIVE To investigate the related factors of fungal infection in invasive pneumonia patients and the effect of itraconazole on pulmonary function and liver function in the treatment of pulmonary fungal infection. METHODS A total of 546 patients with pneumonia in our hospital from Sep. 2015 to Dec. 2016 were chosen. Fungal infection of patients with pneumonia was taken for statistics, and the risk factors of fungal infection in patients were analyzed. The pulmonary function and liver function before and after treatment of itraconazole in patients with pulmonary fungal infection were detected. RESULTS Totally 611 strains of pathogens were detected in 546 infected patients. Among them, gram-negative bacteria, gram-positive bacteria and fungi were 321, 179 and 111 strains, respectively, and the composition ratios were 52.54%, 29.30% and 18.17%. Of the 546 cases, 111 cases were fungal infection, accounting for 20.33%. Age, hospitalization time, invasive operation, long-term application of hormones, long- term application of immunological agents, invasive operation history and underlying diseases were the independent risk factors for fungal infection in pneumonia patients (P<0.05). After treatment, the maximal expiratory volume first seconds expiratory volume (FEV1), forced expiratory volume (FVC), FEV1/FVC and FEV1/FVC (FEV1) were (1.97±0.03)L, (2.98±0.06)L, (65.38±7.34)% and (64.38±5.88)%, and had significant differences compared with those before treatment(P<0.05). There was no significant difference in the liver function indexes of the patients before and after treatment. CONCLUSION Using itraconazole in the treatment of pulmonary fungal infection will not have a significant effect on the patient's liver while improving the lung function of the patients.